Asset Details
Do you wish to reserve the book?
Fertility rates and birth outcomes after ChAdOx1 nCoV-19 (AZD1222) vaccination
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Fertility rates and birth outcomes after ChAdOx1 nCoV-19 (AZD1222) vaccination
Do you wish to request the book?
Fertility rates and birth outcomes after ChAdOx1 nCoV-19 (AZD1222) vaccination
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Fertility rates and birth outcomes after ChAdOx1 nCoV-19 (AZD1222) vaccination
2021
Overview
Despite the absence of supporting evidence for such a risk, low biological plausibility, and preliminary data supporting the safety of mRNA vaccines in pregnancy,1–3 this claim has become widespread, and it has been challenged by WHO.4 Vaccine hesitancy during pregnancy, or among women of childbearing age, could have substantial public health consequences because infection with SARS-CoV-2 during pregnancy is a risk factor for severe maternal illness and complications.5,6 We have analysed pregnancies that have occurred in four ongoing phase 1, phase 2, and phase 3 clinical trials of ChAdOx1 nCoV-19 (AZD1222)7 in three countries (NCT04324606 and NCT04400838 in the UK; NCT04536051 in Brazil; and NCT04444674 in South Africa). [...]termination of pregnancy is illegal in Brazil, and uncertainty remains about whether the reports of early pregnancy losses were all miscarriages. [...]a combined analysis of either miscarriage or termination was done for all sites (table 2), with separate subgroup analyses for termination alone and for miscarriage alone, excluding the Brazilian data. Supplementary Material Supplementary appendix ChAdOx1 nCoV-19 (n=4925) Control (n=4830)* Fertility rate ratio (95% CI) p value Pregnant women (fertility rate)† 50 (0·0102) 43 (0·0089) 1·14 (0·76–1·71) 0·53 Viable pregnancies (fertility rate)‡ 32 (0·0065) 29 (0·0060) 1·08 (0·66–1·79) 0·80 Table 1 Fertility rates ChAdOx1 nCoV-19 (n=72) Control (n=35) Risk ratio (95% CI) p value Miscarriage, excluding Brazilian data 6/43 (14%) 5/24 (21%) 0·67 (0·23–1·97) 0·51 Termination, excluding Brazilian data 8/43 (19%) 6/24 (25%) 0·74 (0·29–1·89 0·55 Miscarriage or termination, all 23/72 (32%) 13/35 (37%) 0·86 (0·50–1·49) 0·67 Preterm birth 3/10 (30%) 0/5 (0%) Not calculable 0·51* Full-term birth 7/72 (10%) 5/35 (14%) 0·68 (0·23–1·99) 0·52 Ongoing pregnancy 39/72 (54%) 17/35 (49%) 1·12 (0·75–1·67) 0·68 Table 2 Pregnancy outcomes
Publisher
Elsevier Ltd,Elsevier Limited,Published by Elsevier Ltd
